Safety and Efficacy of Tideglusib in Congenital or Childhood Onset Myotonic Dystrophy

Clinical trial NCT05004129 · RECRUITING

Trial details

NCT number: NCT05004129
Sponsor: AMO Pharma Limited
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Congenital Myotonic Dystrophy

Start date: 2021-08-23
Primary completion: 2026-12-31
Enrollment: 76

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.